Menoufia University

Fenofibrate, a PPARα agonist, significantly improves clinical outcomes and reduces inflammation in mild to moderate ulcerative colitis (UC) patients when combined with mesalamine, according to a randomized, double-blind, controlled clinical study. The study found that fenofibrate enhances the digestive domains of the IBDQ-32, reduces inflammatory markers like NLRP3 and fecal calprotectin, and upregulates SIRT1 and AMPK. The combination therapy is safe and tolerable, suggesting further investigation for UC treatment.